Annovis secures IP protection for both forms of buntanetap

MALVERN, Pa. - Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage pharmaceutical company with a current market capitalization of $52 million, announced Thursday it has completed the transfer of all patents to cover both the original semi-crystalline and new crystalline forms of its drug candidate buntanetap, extending protection until 2046. According to InvestingPro data, the company maintains a strong balance sheet with cash reserves exceeding debt obligations.

The neurodegenerative disease-focused company said its intellectual property now encompasses 13 patent families filed internationally, providing global coverage for both forms of the drug, which is being developed for conditions including Alzheimer’s and Parkinson’s disease.

According to the company’s press release statement, Annovis has expanded its IP portfolio beyond its foundational patent to include protection for composition of matter, mechanism of action, multiple indications, and potential combinations with other drugs.

The company noted that animal and human studies demonstrated bioequivalence between the two forms of buntanetap, with identical systemic exposure. These findings were presented at the Alzheimer’s Association International Conference 2025 in Toronto.

"With full IP protection now in place for both forms of buntanetap, we are well-positioned to continue its development and fully explore its therapeutic potential," said Maria Maccecchini, President and CEO of Annovis.

The FDA previously approved the use of the new crystalline form for the company’s ongoing Phase 3 clinical trial in early Alzheimer’s disease. This trial, which began earlier this year, involves participants receiving either placebo or crystal buntanetap daily for 18 months, with over 75 sites secured across the US.

Annovis is developing buntanetap as a treatment for neurodegenerative diseases, focusing on its ability to suppress multiple pathologies simultaneously.

In other recent news, Annovis Bio Inc. reported its first-quarter results for 2025, prompting analysts to adjust their projections. Canaccord Genuity reduced its price target for Annovis Bio to $17.00 from $26.00, while maintaining a Buy rating on the stock. Similarly, H.C. Wainwright lowered its price target to $12.00 from $30.00, but also kept a Buy rating. These revisions are influenced by Annovis Bio’s recent equity financing and the ongoing Phase 3 trial for buntanetap, a drug aimed at treating early Alzheimer’s disease.

The trial is a significant study involving approximately 750 patients across about 100 clinical sites in the United States. Canaccord Genuity analysts have incorporated a 25% probability of buntanetap’s approval into their financial models, with a potential market launch anticipated in 2028. The drug’s annual price is expected to remain at $17,500. These developments reflect the company’s ongoing efforts and the cautious optimism among analysts regarding its future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.